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Abstract
Background: Ghrelin, a natural growth hormone secretagogue (GHS), has been identified in prostate
carcinoma cell lines.
Objectives: To investigate the presence of ghrelin and its receptors in human prostate tumours and in
DU-145, PC-3 and LNCaP prostate carcinoma cell lines, and to assesss the effects of ghrelin and its
more abundant circulating form, des-octanoyl ghrelin, on cell proliferation.
Methods: Ghrelin and types 1a and 1b GHS receptor (GHS-R) were determined at the mRNA and
protein levels by RT-PCR, in situ hybridization, immunohistochemistry and enzyme immunoassay
in tissues, cell lines and culture medium. Ghrelin binding was determined by radioreceptor assay.
The effects on cell proliferation were evaluated by growth curves.
Results: Ghrelin mRNA was found in prostatic carcinomas and benign hyperplasias, but immuno-
histochemistry was negative. GHS-R1a and 1b mRNAs were absent from carcinomas, but GHS-
R1b mRNA was present in 50% of hyperplasias. Ghrelin peptide and mRNA were present in PC-3
cells exclusively, whereas GHS-R1a and 1b mRNAs were expressed in DU-145 cells only. Specific
[125I]Tyr4-ghrelin binding was detected in prostate tumour, DU-145 and PC-3 cell membranes and
the binding was displaced by ghrelin, synthetic GHS and des-octanoyl ghrelin, which is devoid of
GHS-R1a binding affinity and GH-releasing activity. Ghrelin and des-acyl ghrelin inhibited DU-145
cell proliferation, displayed a biphasic effect in PC-3 cells and were ineffective in LNCaP cells.
Conclusions: Specific GHS binding sites, other than GHS-R1a and 1b, are present in human prostatic
neoplasms. Ghrelin, in addition to des-acyl ghrelin, exerts different effects on cell proliferation in pros-
tate carcinoma cell lines.
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Introduction
Ghrelin is a gastrointestinal hormone, identified in the
rat and human stomach, that stimulates the release of
growth hormone (GH), gut motility and food intake
and causes positive energy balance (1–3). It is an acyl
peptide consisting of 28 amino acids and esterified
with octanoic acid on Ser3, although a form of 27
amino acids, des-Gln14-ghrelin (resulting from alterna-
tive splicing of the same gene) has also been isolated (4).
Both forms exist in either acylated and, more abun-
dantly, des-acylated forms (5), but the latter have been
shown to be inactive in terms of GH-releasing activity
in vivo (6, 7). Ghrelin expression has also been described
in the pituitary gland, the arcuate nucleus of the hypo-
thalamus, kidney, placenta, endocrine pancreas, testis
(8 –13) and in various endocrine neoplasms of pituitary,
gastrointestinal and pancreatic origin (12, 14, 15).
The effects of ghrelin are mediated by specific receptors
shared by non-natural compounds of the GH secreta-
gogue (GHS) family, such as hexarelin and MK-0677
(16, 17). Two types of GHS receptor (GHS-R) have
been cloned: the GHS-R type 1a and its inactive isoform,
GHS-R1b, which are widely distributed in different
regions of the brain, pituitary gland and other periph-
eral organs (18–20). GHS-R1a mediates the classical
GH-releasing effect, in addition to some non-endocrine
activities, whereas various uncloned GHS binding sites
seem to be involved in mediating other non-endocrine
actions, the significance and relevance of which are cur-
rently poorly understood (3, 21). The latter include
inhibition of cell growth in neoplastic cells, as observed
in thyroid, breast and lung tumours (22 –25). Interest-
ingly, the different binding pattern of natural and syn-
thetic GHS ligands in some non-tumoural and
neoplastic tissues or cell lines seemed to suggest
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the possible existence of specific GHS-R subtypes differ-
ent from the GHS-R1a (3, 23, 26, 27). The recent find-
ings that breast cancer cell lines, H9c2 cardiomyocytes
and guinea pig heart do not express GHS-R1a, but have
high-affinity binding sites, common for ghrelin and
des-acyl ghrelin, that are involved in mediating their
antiproliferative, cardioprotective and negative cardiac
inotropic effects, provide further support to the
hypothesis that several receptors for ghrelin and GHS
exist in normal and neoplastic tissues (23, 26, 27).
Each receptor may then contribute independently to
the wide array of biological activities induced by syn-
thetic GHS, ghrelin and endogenous ghrelin-derived
molecules (3, 28).
At present, no data are available on the expression of
ghrelin and GHS-R in human prostate carcinomas or in
benign prostatic hyperplasias. However, a recent study
reported the presence of ghrelin at both mRNA and
peptide levels in various prostate carcinoma cell lines
(29). This expression was accompanied by the presence
of GHS-R1a. When the activity of ghrelin on cell pro-
liferation was studied in one of the cell lines (PC-3), a
mitogenic effect was found at low concentrations of
the peptide (0.1 –20 nmol/l). To clarify a possible auto-
crine/paracrine role of ghrelin in prostatic tumours, the
effect of this hormone, and that of its endogenous des-
acylated form, on the proliferation of cultured prostatic
carcinoma cells should be validated by using a wide
range of concentrations of ghrelin and by examining
the expression of ghrelin and GHS-R on benign and
malignant human prostatic neoplasms.
On the basis of the foregoing, the aims of the present
study were first to investigate the expression of ghrelin
in benign (hyperplastic) and malignant (carcinoma-
tous) prostatic tissues and in one androgen-dependent
(LNCaP) and two androgen-independent (DU-145 and
PC-3) prostatic carcinoma cell lines. In addition, in
the above cells and tissues, the presence of GHS-R
was assessed either by RT-PCR or by binding studies.
Finally, we studied the effects of ghrelin, des-octanoyl
ghrelin and some synthetic peptidyl (hexarelin) and
non-peptidyl (MK-0677) GHSs on the proliferation of
DU-145, PC-3 and LNCaP human prostate carcinoma
cell lines in vitro.
Materials and methods
Chemicals
Human ghrelin(1 – 28), ghrelin (human) enzyme immu-
noassay kit and anti-human ghrelin polyclonal anti-
body were purchased from Phoenix Pharmaceuticals
Inc. (Belmont, CA, USA). Hexarelin, MK-0677 and
Tyr4-ghrelin(1 – 28) were purchased from Neosystem
SA (Strasbourg, France), and growth hormone-releas-
ing hormone (GHRH)(1 – 29) and somatostatin release-
inhibiting factor (SRIF)(1 – 14) were from Bachem
Feinchemikalien AG (Bubendorf, Switzerland).
[125I]Tyr4-ghrelin (1800 –2100 Ci/mmol) and [3H]thy-
midine (specific activity 2000 Ci/mmol) were pur-
chased from Amersham Biosciences. Ghrelin was
radioiodinated using a lactoperoxidase method and
purified by reverse-phase high-performance liquid chro-
matography. Insulin-like growth factor (IGF)-I, penicil-
lin, streptomycin, FCS, trypsin/EDTA solution and
other tissue culture reagents were purchased from
Sigma Aldrich Srl.
Tissue samples and cell lines
Ten surgical specimens of benign prostatic hyperplasia
and 13 samples of prostatic carcinoma, including
three neuroendocrine carcinomas, were obtained from
the Department of Pathology. All patients gave their
informed consent for the research use of their tissues
and the study obtained approval from an independent
local Ethics Committee. A small fragment of tissue adja-
cent to the portion taken for histopathological examin-
ation was immediately frozen at 280 8C and stored for
4 –24 months until processed for RNA extraction,
immunohistochemistry, in situ hybridization, mem-
brane preparation and binding studies.
DU-145, PC-3 and LNCaP cell lines were purchased
from the American Tissue Culture Collection (Rockville,
MD, USA). Two of them (DU-145 and PC-3) were
androgen-independent (30, 31), whereas LNCaP was
an androgen-dependent cell line (32). DU-145 cells
were routinely cultured in Iscove, and PC-3 and
LNCaP were grown in RPMI 1640 medium sup-
plemented with 10% fetal calf serum (FCS) and penicil-
lin (5000 U/ml)/streptomycin (15 mg/ml) in a 5% CO2
humidified atmosphere at 37 8C. These cultures were
used for RNA extraction, immunohistochemistry, in
situ hybridization and cell proliferation studies, and to
obtain cell membranes for binding.
RT-PCR for ghrelin and GHS-R1a and 1b
In 10 cases of prostatic benign hyperplasia and 10
cases of prostatic carcinoma, and in the three cell
lines of prostate carcinoma studied, RT-PCR was per-
formed to detect mRNAs for ghrelin and types 1a and
1b GHS-R. Total RNA extraction and complementary
DNA transcription were performed as described else-
where (33). The primers for ghrelin were synthesized
according to the sequence reported by Gualillo et al.
(11). The sequences were: 50-TGAGCCCTGAACACCAG-
AGAG-30 for the forward primer and 50-AAAGCCAGA-
TGAGCGCTTCTA-30 for the reverse primer. Those for
GHS-R1a and 1b were synthesized according to Korbo-
nits et al. (14) and used for RT-PCR under the same
conditions as described by these authors. The following
sequences were used: 50-TCGTGGGTGCCTCGCT-30 as
the forward primer for both GHS-R1a and GHS-R1b,
50-CACCACTACAGCCAGCATTTTC-30 for the GHS-R1a
reverse primer and 50-GCTGAGACCCACCCAGCA-30 for
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the GHS-R1b reverse primer. The reverse primers are
specific for the two different C-terminal sequences of
GHS-R1a and 1b respectively. In particular, the GHS-
R1b reverse primer recognizes part of the 74 bp
unspliced intron that is characteristic of GHS-R1b tran-
script. The expected sizes of the amplicons were 327 bp,
65 bp and 66 bp for ghrelin, GHS-R1a and GHS-R1b
respectively. Amplification of b2-microglobulin served
as a quality control for the RNA [see details in (12)].
Positive controls included normal gastric mucosa for
ghrelin, and pituitary tissue for GHS-R1a and 1b ampli-
fications. Negative controls were carried out by
omitting cDNA from the PCR mixture and the reverse
transcriptase enzyme during retrotranscription.
To test the specificity of the RT-PCR product further,
Southern blot analysis was performed using the probe
sequence (50-TCCGGTTCAACGCCCCCTTTG-30) pre-
viously published by Korbonits et al. (14). Membranes
were hybridized overnight at 42 8C with 25 pmol
digoxigenin-labelled ghrelin and GHS-R oligonucleotide
probes. The membranes were then washed with 2 £
SSC –0.1% SDS for 5 min at 42 8C and 0.5 £ SSC –
0.1% SDS at 42 8C for 10 min. Digoxigenin-labelled
specific hybridization was visualized using an immuno-
logical detection system (Boehringer Mannheim
Gmbh) using anti-digoxigenin antibodies conjugated
with alkaline phosphatase. Detection was performed
using the chemiluminescent substrate disodium 3-(4-
methoxyspiro; 1,2-dioxetane-3,2-(5-chloro) tricyclo
(3.3.1.) decan; -4-yl) phenylphosphatase (Boehringer
Mannheim Gmbh), according to the manufacturer’s
instructions. All blots were exposed to X-ray films at
room temperature for 1–5 h.
In situ hybridization for detection of ghrelin
mRNA
Selected cases of benign prostatic hyperplasias (four
cases) and of prostatic carcinomas (four cases) were
studied by means of a non-radioactive in situ hybridiz-
ation procedure in order to confirm the RT-PCR finding
and to analyse the localization of ghrelin mRNA.
Silane-coated slides were hybridized overnight with an
equimolar mixture of two 45mer antisense probes cor-
responding to nucleotides 90–134 and 421–465 of
the pre-pro-ghrelin sequence, at the final dilution of
33 nmol/l (1). Probes were digoxigenin-labelled with
the Boehringer labelling kit, according to the manufac-
turer’s instructions. Prehybridization treatments
included a microwave passage (5 min at 800 W in
citrate buffer pH 6.0) and proteinase K digestion
(1mg/ml) for 4 min. Hybridization products were
revealed applying the Dako GenPoint kit (Dako A/S,
Glostrup, Denmark) as described elsewhere (33), with
the following minor modifications: a 1/5 dilution of tyr-
amide was used and the sample was washed with hot
PBS after the tyramide incubation (34). Positive con-
trols were represented by sections of normal oxyntic
mucosa of the stomach. In order to test the specificity
of the antisense probes and to exclude a possible tyr-
amide-based background, negative controls were also
run, such as hybridization with an unrelated probe,
omission of the specific probe, and RNase digestion.
Immunohistochemistry for detection of
ghrelin in tissue and cell lines
Sections from surgical specimens of benign prostatic
hyperplasia and prostatic carcinoma were collected
onto poly-L-lysine-coated slides; DU-145, PC-3 and
LNCaP cells were grown on glass coverslips and fixed
using methanol (5 min at 220 8C) and acetone (5 s at
220 8C), and stained for ghrelin using a standard
immunoperoxidase procedure with streptavidin peroxi-
dase (StrAviGen MultiLink kit, BioGenex Laboratories
Inc., San Ramon, CA, USA). Slides were incubated
with a 1/3000 dilution of an anti-human ghrelin anti-
body for 1 h at room temperature and the antigen was
revealed as described previously (35). Anti-ghrelin anti-
body is a rabbit polyclonal antiserum that recognizes
the C-terminal portion of both acylated and des-acy-
lated ghrelin. After incubation with the primary anti-
body, the slides were incubated for 20 min with the
secondary biotinylated antibody and then with a
1/50 dilution of the streptavidin–peroxidase conjugate
for another 20 min. Finally, 3-30-diaminobenzidine
chromogen solution (LiquidDAB Substrate Pack, Bio-
Genex Laboratories) was used to reveal the final reac-
tion product and slides were counterstained in
Mayer’s haematoxylin (BioGenex Laboratories) for
30 s, dehydrated and mounted. Negative control reac-
tions for ghrelin included omission of the primary anti-
body and preabsorption with a 100-fold excess of the
antigen, as described elsewhere (15). The positive con-
trol for ghrelin was the endocrine cells of the oxyntic
mucosa of the stomach.
Enzyme immunoassay for the detection of
ghrelin in culture medium
In order to evaluate the secretion of ghrelin by prostate
carcinoma cells, the peptide was assayed in the culture
medium of cancer cell lines immunoreactive for ghre-
lin, by means of an enzyme immunoassay (EIA) tech-
nique. In a 75 ml flask, cells were grown until
subconfluent. Medium was collected from the flasks
and ghrelin was assayed in accordance with the
instructions for the ghrelin (human) EIA kit. Control
culture medium, in which human ghrelin was added
at concentrations ranging from 10 to 100 pmol/l, was
used as positive control.
Ghrelin binding assay
Ghrelin binding to membranes (30 000 g pellet) iso-
lated from tumour tissues or cell line cultures was
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carried out as described previously (17, 26, 27) using
[125I]Tyr4-ghrelin as a radioligand. Tyr4-ghrelin has
been reported to have, in vivo, the same GH-releasing
potency as native ghrelin and to be a reliable probe
for labelling GHS-R in human tissues (6, 17). For the
single-point binding assay, cell membranes [corre-
sponding to 100mg membrane protein measured
using the method of Lowry et al. (36)] were incubated
in triplicate at 23 8C for 2 h under constant shaking
with approximately 1 nmol/l [125I]Tyr4-ghrelin in a
final volume of 0.5 ml assay buffer. The composition
of the assay buffer was as follows: 50 mmol/l Tris,
2.5 mmol/l EGTA, 0.002% bacitracin, 0.1% BSA,
titrated to a final pH of 7.4 with HCl. Parallel incu-
bations, in which 2.0mmol/l unlabelled ghrelin was
also present, were used to determine non-specific bind-
ing, which was subtracted from total binding to yield
specific binding values.
The binding reaction was terminated by the addition
of ice-cold assay buffer, followed by filtration through
Whatman GF/B filters. Filters were rinsed three times
with assay buffer and the radioactivity bound to mem-
branes was measured by a Packard auto-g counter.
Specific binding was expressed as a percentage of the
total radioactivity added. Precautions were taken to
minimize experimental variations in the binding of
[125I]Tyr4-ghrelin to tissue or cell membranes. Thus
all binding studies related to one membrane prep-
aration were carried out using the same batch of radio-
tracer. In some assays, receptor binding saturation
studies were also conducted by incubating tissue mem-
branes with increasing concentrations (from 0.03 to
3 nmol/l) of radioligand in the absence and in the pre-
sence of a fixed amount (2.0mmol/l) of unlabelled ghre-
lin. Saturation isotherms were transformed using the
method of Scatchard (37) and the dissociation constant
(Kd) and number of binding sites (Bmax) were calculated
with the Prism 3 program (GraphPad Software, San
Diego, CA, USA). To establish binding site specificity,
increasing concentrations of various unlabelled
competitors were tested in competition assays with
[125I]Tyr4-ghrelin. The concentration of a competitor
agent causing 50% inhibition of specific radioligand
binding (IC50 value) was derived from the iterative
curve-fitting analysis.
Cell proliferation studies
Cell proliferation was evaluated either by the incorpor-
ation of [3H]thymidine into DNA or by counting the
number of cells after appropriate incubation with
different compounds.
Studies of [3H]thymidine incorporation were per-
formed as described previously (22 –24). Briefly, starved
DU-145 prostate cancer cells (2 £ 105 cells/ml) were
incubated at 37 8C, with or without 20 ng/ml IGF-I in
the absence or the presence of different concentrations
(from 0.1 nmol/l to 1mmol/l) of ghrelin, des-octanoyl
ghrelin, hexarelin, MK-0677 and GHRH. After 20 h,
[3H]thymidine 1mCi/well was added and the incu-
bation was continued for further 4 h, when the cells
were harvested onto glass-fibre filter strips. Incorpor-
ation of [3H]thymidine was measured in a scintillation
counter.
In the experiments involving a study of cell numbers,
DU-145, PC-3 and LNCaP cells were seeded in triplicate
in 48-multiwell plates (2–4 £ 103 cells/well) in stan-
dard culture medium and allowed to become attached
for 24 h. At 8 h after plating, cells were synchronized,
by being left for 36 h in 0.5% FCS. They were then
grown in a standard culture medium for 48 h in the
absence or the presence of different concentrations of
ghrelin or des-octanoyl ghrelin (10 pmol/l to
1mmol/l). After 48 h of treatment, cells were fixed in
2.5% glutaraldehyde, stained with 0.1% crystal violet
in 20% methanol and solubilized in 10% acetic acid.
Cell growth was evaluated by measuring absorbance
at 590 nm in a microplate reader (Multiskan Bichro-
matic, Thermo-Labsystems Oy, Helsinki, Finland). A
calibration curve was set up with known numbers of
cells and a linear correlation between absorbance and
cell counts was established up to 1 £ 105 cells. For
time-course studies, DU-145 and PC-3 cells were trea-
ted as in the previous experiment, except that
0.5 £ 103 cells were seeded per well and cell growth
was followed in the absence or the presence of low
(10 pmol/l) or high (1mmol/l) concentrations of ghre-
lin or des-octanoyl ghrelin at more than one time
point (24, 48, 72 and 96 h after adding the hormone),
with a change of medium every 48 h.
Statistical analysis
Values are expressed as median and range unless
otherwise noted. In competition binding experiments
and in cell proliferation studies, data are given as
mean^S.E.M. The number of cases or experiments is
indicated as n. Significant differences between groups
were assessed by Kruskal–Wallis or Duncan’s multiple
range test. P,0.05 was chosen as the level of
significance.
Results
Expression of ghrelin mRNA and peptide
All cases of either benign prostatic hyperplasia or pro-
static carcinomas were positive for expression of ghrelin
mRNA, as studied by RT-PCR. This is depicted in Fig. 1,
in which two representative example are given for both
conditions: lanes 4 and 5, and 6 and 7 respectively. PC-
3 cells (lane 3) were also positive, whereas DU-145
(lane 1) and LNCaP (lane 2) were negative. Analysis
of mRNA by means of in situ hybridization confirmed
the RT-PCR positivity for ghrelin mRNA in both
benign prostatic hyperplasia (Fig. 2A) and prostatic
176 P Cassoni and others EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004) 150
www.eje.org
cancer (results not shown). In contrast, none of the
cases of benign prostate hyperplasia (Fig. 2B) or carci-
noma, whether neuroendocrine or non-neuroendo-
crine (not shown), was immunoreactive for ghrelin.
Anti-human ghrelin polyclonal serum stained a large
percentage (.80%) of ghrelin-positive cells in the PC-
3 cell line (Fig. 3A), whereas it did not reveal any posi-
tive cells in DU-145 (Fig. 3B) or LNCaP (Fig. 3C) cell
lines. The omission of the primary antibody or preab-
sorption with excess of antigen gave negative immuno-
staining in the PC-3 cell line (data not shown).
Ghrelin in cell culture medium
Using the EIA kit, no ghrelin was found in the medium
collected from the culture flasks of subconfluent pros-
tate carcinoma cells immunoreactive for ghrelin (PC-3
cell line).
Expression of GHS-R1a and 1b mRNAs
Expression of GHS-R1a and 1b mRNAs was evaluated
by RT-PCR. After RT-PCR (Fig. 4), a 65 bp and a 66 bp
signal, corresponding to GHS-R1a and GHS-R1b
mRNAs respectively, were observed (lane C þ ) in a
classic ghrelin target tissue, such as the pituitary
gland (8, 17). In contrast, no signal corresponding
to GHS-R1a was detected in either prostatic hyperpla-
sia (two representative cases shown in lanes 4 and 5)
or prostatic cancer (lanes 6 and 7) tissues. A signal
corresponding to GHS-R1b was detected in five of 10
cases of benign prostatic hyperplasia (examples of a
positive and a negative case given in lanes 4 and 5),
but none of the cancer cases was positive for GHS-
R1b (lanes 6 and 7). Conversely, mRNA for both
GHS-R1a and 1b was found in DU-145 cells (lane 1),
whereas no signal for either GHS-R was observed in
LNCaP (lane 2) and PC-3 cells (lane 3), as confirmed
by Southern blot analysis. Moreover, no signal was
detected in an otherwise positive sample, when RT
enzyme was omitted (lane C 2 ).
Ghrelin binding studies
[125I]Tyr4-ghrelin binding was observed in both benign
and malignant prostate tumours. Specific binding of
ghrelin was observed in all tissue specimens examined
and represented about 55–64% of total radioactivity
Figure 1 Detection by RT-PCR of mRNA for ghrelin in human
prostate tumours and DU-145, PC-3 and LNCaP prostate cancer
cell lines. The 327 bp band in lanes 1, 2 and 3 corresponds to
ghrelin mRNA expressed by DU-145, LNCaP and PC-3 prostate
cancer cell lines; lanes 4–5, benign prostatic hyperplasias (two
selected cases among 10); lanes 6–7, prostatic carcinoma tissues
(two selected cases among 13). C 2 , negative control (omission
of cDNA in the PCR mixture); C þ , gastric mucosa used as a
positive control; MW, molecular mass markers.
Figure 2 (A) In situ hybridization of ghrelin mRNA and (B) ghrelin
immunoreactivity in human benign prostatic hyperplasia.
(C) Negative control for in situ hybridization, performed using an
unrelated probe. In situ hybridization and immunohistochemistry
were conducted as described in Materials and methods. Original
magnifications, £ 400.
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bound. A considerable specific binding was also found in
two (DU-145 and PC-3) of three human prostate cancer
cell lines examined, in which it represented 59–71% of
total radioactivity bound. Ghrelin binding was very high
in the androgen-independent cell line DU-145, with
values that were twofold greater (P , 0.05) than
those of the other androgen-independent cell line
(PC-3) or those previously found (22–31 fmol/mg
protein) in the human pituitary gland (17). In contrast,
negligible ghrelin binding values (less than 0.2%) were
detected in the androgen-dependent LNCaP prostate
cancer cells (Table 1). Experiments using increasing
concentrations of [125I]Tyr4-ghrelin provided evidence
for a saturable specific binding in benign prostate hyper-
plasia, prostate carcinomas, DU-145 and PC-3, but not
in LNCaP cells (Fig. 5). Scatchard analysis of these data
(data not shown) demonstrated the existence of high-
affinity sites with limited binding capacity (Bmax) in
benign and malignant neoplasms, and in DU-145 and
PC-3 cell lines. No difference in the Kd values was
observed among prostate tumours, DU-145 and PC-3
cells, whereas the number of receptors varied, showing
a greater binding capacity in the DU-145 cell line
(Table 1).
The specificity of [125I]Tyr4-ghrelin binding to mem-
branes from those samples of prostate tumours (carci-
nomas) that yielded sufficient amounts of membranes
and from DU-145 or PC-3 cell lines was established
by competitive binding experiments. In these, either
ghrelin or des-octanoyl ghrelin was used, the latter
an endogenous ghrelin derivative (5) devoid of binding
affinity for GHS-R1a (38) and of GH-releasing activity
in vivo (6, 7). Some synthetic peptidyl (hexarelin) and
non-peptidyl (MK-0677) GHS, in addition to two hypo-
thalamic neuropeptides (GHRH and SRIF) structurally
Figure 4 Expression of mRNA for GHS-R types 1a and type 1b in
human prostate tumours and related cancer cell lines, demon-
strated by Southern blot analysis of RT-PCR products. C 2 ,
negative control (omission of cDNA in the PCR mixture and the
reverse transcriptase enzyme during retrotranscription); C þ ,
pituitary gland used as a positive control. The 65 and 66 bp bands
correspond to RT-PCR products for GHS-R1a and 1b respect-
ively. Lanes 1, 2, 3 are for DU-145, LNCaP and PC-3; lanes 4–5,
benign prostatic hyperplasias (two selected cases among 10);
lanes 6–7, prostatic carcinoma tissues (two selected cases
among 13).
Table 1 [125I]Tyr4-ghrelin binding to membranes of human prostate neoplasms and DU-145, PC-3 and LNCaP prostate cancer cell
lines.
Tissue or cell line Specific binding (% radioactivity added/0.1 mg protein) Bmax (fmol/mg protein) Kd (nmol/l)
Prostate neoplasms
Benign hyperplasias (n ¼ 6) 1.00 (0.60–1.70) 24.0 (12.0–32.0) 0.55 (0.40–0.60)
Carcinomas (n ¼ 3) 1.50 (0.70–2.80) 38.0 (22.0–44.0) 0.55 (0.39–0.86)
Prostate carcinoma cell lines
Du-145 (n ¼ 4) 3.21^0.22* 62.0^5.0* 0.47^0.05
PC-3 (n ¼ 4) 1.40^0.06 33.3^3.4 0.59^0.07
LNCaP (n ¼ 4) 0.17^0.03 n.d. n.d.
Values are median (range) or mean^S.E.M. n, number of cases or experiments; n.d., not detectable. *P , 0.05 compared with PC-3 cells or prostate
carcinomas.
Figure 3 Ghrelin immunoreactivity in (A) PC-3, (B) DU-145 and (C) LNCaP cell lines. Original magnifications, £ 400.
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unrelated to ghrelin, were also studied in these com-
petitive binding experiments. [125I]Tyr4-ghrelin bound
to membranes of prostate carcinomas (Fig. 6A) and
DU-145 cells (Fig. 6B) was completely displaced in a
dose-dependent manner by unlabelled ghrelin, hexare-
lin, MK-0677 and, surprisingly, by des-octanoyl ghre-
lin, all of which exhibited high-affinity binding values
(Table 2). In contrast, no competition was observed in
the presence of GHRH or SRIF. The specificity of displace-
ment observed in the PC-3 cell line was quite similar to
that observed in the DU-145 cells (data not shown).
Effects of ghrelin, des-octanoyl ghrelin and
synthetic GHS on prostate cancer cell
proliferation
Both acylated and des-acylated ghrelin, in addition to
hexarelin and MK-0677, inhibited the IGF-I-stimulated
incorporation of thymidine in DU-145 cells, at concen-
trations close to their binding affinities reported in
Table 2 (Fig. 7). The calculated 50% effective doses
(mean^S.E.M. of four separate experiments) were
8.0^1.4 nmol/l for ghrelin, 13.1^2.0 nmol/l for des-
octanoyl ghrelin, 21.9^3.1 nmol/l for hexarelin and
41.0^4.4 nmol/l for MK-0677. In contrast, no inhi-
bition was observed in the presence of GHRH, which
was unable to displace [125I]Tyr4-ghrelin from mem-
branes of DU-145 cells. In addition, no change in thy-
midine incorporation was observed when the different
compounds were incubated with DU-145 cells growing
in the absence of IGF-I (i.e. under basal conditions).
Figure 5 Representative saturation of [125I]Tyr4-ghrelin binding to
membranes obtained from a benign prostate hyperplasia, a pros-
tate carcinoma and prostate cancer cell lines DU-145, PC-3 and
LNCaP. Experiments were performed by incubating a fixed
amount of membrane protein (100mg/tube) with increasing con-
centrations of radiolabelled ghrelin, either alone (total binding) or
together with unlabelled ghrelin (2.0mmol/l) (non-specific binding).
Specific binding values were obtained by subtracting non-specific
binding from total binding.
Figure 6 Displacement of [125I]Tyr4-ghrelin bound to membranes
from (A) prostate carcinomas and (B) DU-145 prostate cancer cell
line, by different unlabelled competitors. Binding assays were con-
ducted as described in Materials and methods. The ordinate rep-
resents binding as a percentage of control (specific binding in the
absence of unlabelled competitor). Values are mean^S.E.M. of
three separate experiments.
Table 2 IC50 values of ghrelin, des-octanoyl ghrelin, hexarelin
and MK-0677 for [125I]Tyr4-ghrelin binding to membranes of
prostate carcinomas and DU-145 prostate cancer cells.
IC50 (nmol/l)
Competitor
Prostate
carcinomas DU-145 cells
Ghrelin 7.6^0.6 7.9^0.4
Des-octanoyl ghrelin 11.3^1.2 15.7^0.9
Hexarelin 19.0^1.7 25.0^3.9
MK-0677 36.7^4.4 38.9^2.0
Values are mean^S.E.M. of three separate experiments.
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The biological effect of ghrelin and des-octanoyl
ghrelin on cell growth was determined at different
concentrations and at various hours of treatment.
Figure 8A shows the dose-dependent effect of ghrelin
in all the three cell lines tested at 48 h of treatment.
Interestingly, low peptide concentrations (10 and
100 pmol/l) stimulated cell growth in PC-3 cells only,
but were ineffective in DU-145 cells (which were inhib-
ited by ghrelin at concentrations ranging from 1 nmol/l
to 1mmol/l). In contrast, no change in cell growth was
observed when LNCaP cells were exposed to different
concentrations of ghrelin. Similar findings concerning
the cell growth of the three cell lines studied were
obtained when they were incubated with des-octanoyl
ghrelin for 48 h (Fig. 8B). Figure 9 shows the time-
course of the effect of acylated and des-acylated ghrelin
on cell growth of DU-145 and PC-3 cell lines at a
concentration (10 pmol/l) that stimulated PC-3 cell
proliferation or at a concentration (1mmol/l) that
inhibited the cell growth of both cell lines. When
added at 1mmol/l concentration, both ghrelin and
des-octanoyl ghrelin were associated, at 48 h, with a
significant decrease in the numbers of DU-145 and
PC-3 cells, compared with controls; by 72 or 96 h
the decrease in cell numbers was even more
evident (Fig. 9). With a low concentration of peptide
(10 pmol/l), both acylated and des-acylated forms of
ghrelin were associated, after 48 h of treatment, with
a significant increase in cell numbers only in PC-3
cells, and this effect was even more evident at 72 or
96 h. In contrast, no change in cell numbers was
observed when DU-145 cells were incubated for periods
up to 96 h with a low concentration (10 pmol/l) of the
above-mentioned peptides.
Discussion
We have shown here for the first time that ghrelin and
GHS receptors are expressed in human prostatic carci-
nomas and benign hyperplasias. We have also shown
that ghrelin and some of its analogues produce different
effects on cell proliferation in three different prostatic
carcinoma cell lines.
Figure 7 Effect of ghrelin, des-octanoyl ghrelin, hexarelin,
MK-0677 and GHRH on basal (dashed line) and IGF-I-stimulated
(solid line) incorporation of [3H]thymidine into DNA by human
DU-145 prostate cancer cells. DNA synthesis was estimated by
incorporation of [3H]thymidine after a 20 h incubation with or with-
out 20 ng/ml IGF-I in the absence or presence of different concen-
trations of the indicated compounds. Data are the average of
duplicate assay determinants and similar results were obtained
in at least two other independent measurements.
Figure 8 Dose–response relationship of (A) ghrelin and (B) des-
octanoyl ghrelin on the proliferation of DU-145, PC-3 and LNCaP
human prostate cancer cell lines. Cells were incubated in the
absence (control) or presence of increasing concentrations of
ghrelin and des-octanoyl ghrelin (ranging from 10 pmol/l to
1mmol/l). Cell numbers were determined at 48 h by a standar-
dized absorbance assay (crystal violet). Values represent the
mean^S.E.M. of three separate experiments. *P,0.01,
**P , 0.001 compared with control.
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We have previously reported a detailed analysis of the
distribution of GHS binding sites in tumoural (22 –24)
and non-tumoural human tissues (39–41) using a
radiolabelled peptidyl GHS, such as [125I]Tyr-Ala-hexa-
relin. More recently, we have demonstrated, using
[125I]Tyr4-ghrelin as a ligand, that ghrelin receptors
are present in the human hypothalamus and pituitary
gland and that ghrelin needs octanoylation to bind
with high affinity to pituitary GHS-R (6, 17). By using
[125I]Tyr4-ghrelin, in addition to RT-PCR and in situ
localization techniques, we have now investigated the
presence of mRNA for ghrelin and types 1a and 1b
GHS-R in 10 cases of prostatic benign hyperplasia and
10 cases of prostatic carcinoma, and in prostatic
cancer cell lines, two androgen-independent (DU-145
and PC-3) and one androgen-dependent (LNCaP).
Interestingly, we found that ghrelin mRNA was pre-
sent in all the prostatic benign (hyperplastic) and
malignant (carcinomatous) tissues. However, none of
these tissues expressed ghrelin at the peptide level.
This suggests that hyperplastic and neoplastic prostatic
cells either are unable to synthesize ghrelin (despite
containing the specific mRNA) or do not retain the pep-
tide in the cytoplasm once they have synthesized it.
Additional possibilities could be insufficient sensitivity
of the EIA kit or that the culture conditions used
were not adequate for the ghrelin cell secretory process.
In the cell lines, ghrelin was present (at both the mRNA
and the peptide level) exclusively in the PC-3 cells, in
contrast to what has previously been reported by Jeffery
et al. (29), who also identified ghrelin expression in DU-
145 and LNCaP cells. In addition, the concentration of
ghrelin in the culture medium of the PC-3 cell line
immunoreactive for ghrelin was not relevant,
suggesting that this cell line is able to synthesize, but
does not secrete, ghrelin.
On the basis of these observations, the functional sig-
nificance of ghrelin in the human prostate remains an
open question: neither prostatic tissue nor cell lines
have significant amounts of ghrelin peptide. Thus
only systemic or exogenous ghrelin could affect the
functionality of prostatic primary tissue or cancer cell
lines. However, at present, other sources of ghrelin in
the reproductive tract cannot be excluded. In this
sense, it was shown that Leydig cells are the primary
site of expression and production of ghrelin in the rat
testis, suggesting that this peptide could influence tes-
ticular function, in addition to that of other organs of
the reproductive system, including the prostate (13).
Moreover, a novel proghrelin isoform has been ident-
ified in mouse testis (42) and, more recently, in the
human prostate, where its expression is upregulated
in cancer tissues when compared with normal histo-
logical tissue (43). Nevertheless, the functional role of
this novel peptide remains unexplored.
Regarding the expression of ghrelin receptors, no
GHS-R1a mRNA was detected by RT-PCR in any of
the tissues examined, whereas mRNA for GHS-R1b
was found in 50% of benign prostatic hyperplasias.
However, although no mRNA for GHS-R1a was
detected in the prostatic tissues, a significant binding
was observed in membranes obtained from both hyper-
plastic and cancerous prostatic tissues. These results
suggest that, in these tumours, a ghrelin receptor sub-
type different from the classical GHS-R1a or 1b could
be present. In agreement with the findings in the pros-
tatic cancer tissues, in the prostatic carcinoma cell lines
also, a discrepancy was found between the RT-PCR
data on ghrelin receptors and binding. No mRNA for
either GHS-R1a or 1b was present in LNCaP and
in PC-3 cells, whereas it was found in DU-145 cells.
Figure 9 Time-course of the effect of ghrelin (—) and des-octa-
noyl ghrelin (- - -) on cell proliferation of (A) DU-145 and (B) PC-3
human prostate cancer cell lines. Cells (500/well) were grown for
96 h in the absence (control) and presence of the indicated com-
pounds; the culture medium was changed every 48 h. The cell
number was determined at the indicated time by a standardized
absorbance assay (crystal violet). Values are means mean^S.E.M.
of three separate experiments. *P,0.01, **P , 0.001 compared
with control.
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[125I]Tyr4-ghrelin binding was very high in DU-145
cells, lower in PC-3 cells and absent from LNCaP
cells, the binding showing properties typical of
ligand –receptor interaction, namely high affinity, satu-
rability and specificity. The most significant finding was
the observation that the binding of the radioligand was
inhibited in a dose-dependent manner by unlabelled
natural (ghrelin) and synthetic GHS (hexarelin and
MK-0677) and, surprisingly, by des-octanoyl ghrelin,
a natural form of ghrelin devoid of GHS-R1a binding
affinity (38) and GH-releasing activity in vivo (6, 7).
This displacement pattern implies that the binding
sites are specific for both acylated and des-acylated
forms of ghrelin, and for peptidyl (hexarelin) and
non-peptidyl (MK-0677) GHS –a finding that further
suggests the presence of a GHS-R subtype different
from the GHS-R1a. Considering that des-octanoyl ghre-
lin (which does not interact with GHS-R1a) was able to
displace [125I]Tyr4-ghrelin in the same manner as
ghrelin, our data suggest that non-classical type 1a
GHS-Rs are mainly expressed in prostate neoplasms
and related cell lines. As observed by Scatchard analysis
of saturation binding curves, the demonstration of a
class of ghrelin binding sites only in DU-145 cells
that also expressed both GHS-R1a and 1b may be
attributable to the fact that the GHS-R1b is unable to
bind ghrelin (3) and that the prostatic ghrelin binding
sites possess a binding affinity (Kd values) quite close to
that of GHS-R1a (6, 17, 38).
The effects of ghrelin and des-octanoyl ghrelin on cell
proliferation also differed among the three cell lines
examined. Ghrelin and des-octanoyl ghrelin were inef-
fective in modulating the growth of LNCaP cells, a
cancer cell line that is devoid of ghrelin binding sites.
In contrast, both peptides inhibited, in a dose-depen-
dent manner, the proliferation of the ghrelin-receptor-
positive cell lines DU-145 and PC-3. Surprisingly, a
biphasic effect of ghrelin and des-octanoyl ghrelin
was observed only in the PC-3 cell line. Low concen-
trations of ghrelin or des-octanoyl ghrelin (10 –
100 pmol/l) were able to stimulate cell growth, whereas
higher doses (10 nmol/l to 1mmol/l) caused a signifi-
cant inhibition. This promoting effect on cell prolifer-
ation in the PC-3 cell line is in agreement with what
was reported by Jeffery et al. (29). However, those inves-
tigators reported no study performed using high peptide
concentrations and no data on the inhibiting effect of
ghrelin and des-octanoyl ghrelin. The biphasic profile
reported here is similar to that described in neoplastic
conditions for other molecules, such as somatostatin
and its analogues (44). The discrepant behaviour of
the three cell lines in relation to cell proliferation in
the presence of ghrelin and des-octanoyl ghrelin
requires further investigation. Possible interpretations
include a different responsiveness to Fas-mediated
apoptosis (45) or to androgen-induced cell growth
(30, 32), and a difference in expression of signal trans-
ducers and activators of transcription (46).
As ghrelin and des-octanoyl ghrelin produced an
almost identical inhibition of IGF-I-stimulated incorpor-
ation of thymidine and cell growth, and as it is known
that des-octanoyl ghrelin does not bind to the GHS-
R1a, this inhibitory effect may involve specific binding
sites other than GHS-R1a. In our previous papers on
breast and lung tumours, we have already suggested
the existence of an alternative ghrelin/GHS receptor
in neoplastic tissues, because in that case also the bio-
logical and pharmacological data did not support GHS-
R1a as the receptor involved (23, 24). The hypothetical
existence of a different GHS-R1a subtype or a mutated
GHS-R, or both, is also supported by the finding that a
number of closely interrelated GHS-R subtypes exist in
various tissues (19, 47, 48) and that some artificial var-
iants of the GHS-R1a, such as the E124-Q mutant, lose
the capacity of binding non-peptidyl GHS (19).
Although we have found that ghrelin and GHS-R are
co-expressed at the mRNA and protein levels in pro-
static cancer cell lines, our data obtained on benign
prostatic hyperplasia and prostatic carcinoma could
not confirm the autocrine/paracrine role of ghrelin in
prostatic tumours.
In conclusion, this study shows that ghrelin and its
receptors are highly expressed in the human hyperplas-
tic and neoplastic prostate tissues, in addition to the
DU-145 and PC-3 prostate cancer cell lines. Moreover,
acylated and des-acylated ghrelin, in addition to syn-
thetic GHS, inhibit DNA synthesis and proliferation of
the above cell lines through binding to a novel, as yet
unidentified, receptor common for ghrelin and des-
octanoyl ghrelin. Taken together, these data suggest a
possible role of ghrelin and its des-acylated form in
the control of neoplastic cell survival and proliferation.
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